Impact of generics competition on prices and utilization of antiepileptic medicines in Bulgaria

Manoela Manova Zornitsa Emilova Mitkova Alexandra Savova Anna Borisova Lily Peikova Javor Mitkov Guenka Petrova   

Open Access   

Published:  Jan 01, 2023

DOI: 10.7324/JAPS.2023.115004
Abstract

Epilepsy is one of the most common neurological disorders with significant economic and social impact. The timely access to therapy for patients is a serious problem as defined by World Health Organization. The aim of this study is to evaluate generics availability, prices, and utilization of antiepileptic medicines in order to identify the hypothesis if the entrance of generics affects the medicines utilization and price variations in the Bulgarian market. The study is performed as a three-step retrospective observational analysis of 16 existing international nonproprietary names, reimbursed by the National Health Insurance Fund during 2014–2020. The study explores the availability of generics and trademarks, along with the utilization of antiepileptic medicines and possible differences in reference price per defined daily dose (DDD) during the observed period. The 7 years review of antiepileptic medicines placed on the market in Bulgaria showed a tendency of decreasing in the number of generic medicines and in consumption despite the stability or the reduction in reference prices per DDD. This fact indicated that different factors and the country’s environment also played an important role and have affected the overall medicines market. A comprehensive generic policy should be developed to ensure timely patient access to treatment and stable level of medicines utilization.


Keyword:     Antiepileptic medicines generic competition prices utilization


Citation:

Manova M, Mitkova ZE, Savova A, Borisova A, Peikova L, Mitkov J, Petrova G. Impact of generics competition on prices and utilization of antiepileptic medicines in Bulgaria. J Appl Pharm Sci, 2023. https://doi.org/10.7324/JAPS.2023.115004

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Australian Institute of Health and Welfare. Epilepsy in Australia. Australian Government 2022. Available via https://www.aihw.gov.au/ reports/chronic-disease/epilepsy-in-australia/contents/treatment-and-management-of-epilepsy

Baftiu A, Johannessen Landmark C, Nikaj V, Neslein IL, Johannessen SI, Perucca E. Availability of antiepileptic drugs across Europe. Epilepsia, 2015; 56(12):e191-7; doi:10.1111/epi.13210. https://doi.org/10.1111/epi.13210

Beghi E, Giussani G, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, Beghi E, Giussani G, Abd-Allah F, Abdela J, Abdelalim A, Abraha HN, Adib MG, Agrawal S, Alandab F, Awasthi A, Ayele Y, Barboza MA, Belachew AB, Biadgo B, Bijani A, Bitew H, Carvalho F, Chaiah Y, Daryani A, Huyen Phuc Do HPD, Dubey M, Endries AYY, Eskandarieh S, Faro A, Farzadfar F, Fereshtehnejad S-M, Fernandes E, Fijabi DO, Filip I, Fischer F, Gebre AK, Tsadik AG, Gebremichael TG, Gezae KE, Ghasemi- Kasman M, Weldegwergs KG, Degefa MG, Gnedovskaya Elena V, Hagos TB, Haj-Mirzaian A, Haj-Mirzaian A, Hassen HY, Hay Simon I, Jakovljevic M, Kasaeian A, Kassa TD, Khader YS, Khalil I, Khan EA, Khubchandani J, Kisa A, Krohn KJ, Kulkarni C, Nirayo YL, Mackay MT, Majdan M, Majeed A, Manhertz T, Mehndiratta MM, Mekonen T, Meles HG, Mengistu G, Mohammed S, Naghavi M, Mokdad AH, Mustafa G, Irvani SSN, Long Hoang Nguyen LHN, Nichols E, Nixon MR, Ogbo FA, Olagunju AT, Olagunju TO, Owolabi MO, Philips MR, Pinilla-Monsalve GD, Qorbani M, Radfar A, Rafay A, Rahimi-Movaghar V, Reinig N, Sachdev PS, Safari H, Safari S, Safiri S, Sahraian MA, Samy AM, Sarvi S, Sawhney M, Shaikh MA, Sharif M, Singh G, Smith M, Szoeke Cassandra E, I, Tabares-Seisdedos R, Temsah M-H, Temsah O, Tortajada-Girbes M, Bach Xuan Tran BXT, Tsegay AAT, Ullah I, Venketasubramanian N, Westerman R, Winkler AS, Yimer EM, Yonemoto N, Feigin VL, Vos T, Murray CJL. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the global burden of disease study. Lancet Neurol, 2019; 18(4):357-75; doi: 10.1016/S1474-4422(18)30454-X https://doi.org/10.1016/S1474-4422(18)30454-X

Berman E, Marom E, Ekstein D, Blatt I, Eyal S. Utilization of antiepileptic drugs in Israel. Epilepsy Behav, 2016; 61:82-5; doi: 10.1016/j. yebeh.2016.05.004. https://doi.org/10.1016/j.yebeh.2016.05.004

Boon P, Dejonghe P, Legros B, Sadzot B, van Rijckevorsel K, Schmedding E. Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET). Seizure, 2008; 17(4):350-7; doi: 10.1016/j.seizure.2007.11.005. https://doi.org/10.1016/j.seizure.2007.11.005

Braoudaki E, Naoum V, Karampli E, Athanasakis K, Kyriopoulos J. Generics policies: a systematic review of their effectiveness. Value Health, 2017; 20(9):A662; doi:10.1016/j.jval.2017.08.1595. https://doi.org/10.1016/j.jval.2017.08.1595

Bunschoten JW, van der Palen J, Sander JW, Thijs RD. Medication burden in epilepsy: exploring the impact of non-epilepsy concomitant drugs load. Seizure, 2020; 81:104-10; doi:10.1016/j.seizure.2020.07.017. https://doi.org/10.1016/j.seizure.2020.07.017

Cameron A, Bansal A, Dua T, Hill SR, Moshe SL, Mantel- Teeuwisse AK, Saxena S. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia, 2012; 53(6):962-9; doi: 10.1111/j.1528-1167.2012.03446.x. https://doi.org/10.1111/j.1528-1167.2012.03446.x

Cherkaoui G, Cheikh A, Razine R, Bnouhanna W, Regragui W, Benomar A, Cherrah Y. Trends in the consumption and cost of antiepileptics in Morocco between 2008 and 2018. Rev Epidemiol Sante Publique, 2022; 70(2):75-81; doi: 10.1016/j.respe.2022.01.127. https://doi.org/10.1016/j.respe.2022.01.127

J?drzejczak J, Marusic P, Haldre S, Majkowska-Zwoli?ska B, Bojinova-Tchamova V, Mameniskiene R, Mindruta I, Ravnik IM, Szupera Z, Sykora P, Verzbickis A, Daniluk J. Current status of epilepsy health care for adult patients from central and eastern European Union countries: a survey of members of the Central Europe Epilepsy Experts Working Group. Seizure, 2013; 22(6):452-6; doi: 10.1016/j.seizure.2013.03.001. https://doi.org/10.1016/j.seizure.2013.03.001

Liang CY, Chiang KL, Hsieh LP, Chien LN. Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: a nationwide retrospective cross-sectional study. Epilepsy Behav, 2022; 126:108450; doi: 10.1016/j.yebeh.2021.108450. https://doi.org/10.1016/j.yebeh.2021.108450

Melkamu P, Animut Y, Minyihun A, Atnafu A, Yitayal M. Cost of illness of epilepsy and associated factors in patients attending adult outpatient department of University of Gondar Referral Hospital, Northwest Ethiopia. Risk Manag Healthc Policy, 2021; 4(14):2385-94; doi: 10.2147/ RMHP.S289113 https://doi.org/10.2147/RMHP.S289113

Ministry of Health. Ordinance on the terms, rules and procedure for regulation and registration of prices for medicinal products. Effective as from 30 April 2013; amended and supplemented SG N. 28 of 6 April 2021.

National Health Insurance Fund. Reports on number of patients and reimbursement amount. Available via https://www.nhif.bg/page/218 (Accessed August 2022).

National Council on Prices and Reimbursement of Medicinal Products. Registry archive during 2014-2020. Available via https://portal. ncpr.bg/registers/pages/register/archive.xhtml

National Statistical Institute of Bulgaria. Population by districts, place of residence and gender. Available via https://www.nsi.bg/bg/ content/2975/.

Ostendorf AP, Gedela S. Effect of epilepsy on families, communities, and society. Semin Pediatr Neurol, 2017; 24:340-7; doi: 10.1016/j.spen.2017.10.007. https://doi.org/10.1016/j.spen.2017.10.007

Poli?-Vižintin M, Štimac D, Šostar Z, Ingrid Tripkovi?. Distribution and trends in outpatient utilization of generic versus brand name psycho-pharmaceuticals during a ten-year period in Croatia. BMC Health Serv Res, 2014; 14:343; doi: 10.1186/1472-6963-14-343. https://doi.org/10.1186/1472-6963-14-343

Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ, 2014; 348:g254; doi: 10.1136/bmj.g254. https://doi.org/10.1136/bmj.g254

Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther, 2010; 15(2):81-93. https://doi.org/10.5863/1551-6776-15.2.81

Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics, 2008; 26(6):463-76; doi: 10.2165/00019053-200826060-00002. https://doi.org/10.2165/00019053-200826060-00002

WHO. Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment 2018. World Health Organization, Oslo, Norway, 2017. Available via https://www.whocc.no/ atc_ddd_index_and_guidelines/guidelines/ (Accessed August 2022).

World Health Organization. Epilepsy. Key facts. 2022. Available via https://www.who.int/news-room/fact-sheets/detail/epilepsy (Accessed June 2022).

Article Metrics

0 Absract views 1 PDF Downloads 1 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required
Similar Articles

Generic competition and drug prices in the Malaysian off-patent pharmaceutical marketOmotayo Fatokun, Mohamed Izham Mohamed Ibrahim, Mohamed Azmi Hassali


Notice: Undefined offset: 1 in /home/japsonli/public_html/articlemodule/searchArticles.php on line 1253